Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Glioma clinical trials
Every US clinical trial registered for Recurrent Glioma — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
13 US clinical trials · 4 currently recruiting
The research picture
Recurrent Glioma has 13 registered US clinical trials, 4 of them open to new participants right now — about 31% of the total.
- 4
- recruiting participants now
- 31%
- of trials open to enrollment
- 1
- in Phase 3–4 (later-stage)
- 5
- top sponsor: National Cancer Institute (NCI)
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
Mayo Clinic
NCT07074756
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
National Cancer Institute (NCI)
NCT05859334
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Baptist Health South Florida
NCT06397560
CARv3-TEAM-E T Cells in Glioblastoma
Marcela V. Maus, M.D.,Ph.D.
NCT05660369
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Institut de Recherches Internationales Servier
NCT04164901
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
NCT03212274
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
Jonsson Comprehensive Cancer Center
NCT05045027
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
NCT03389230
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03698994
Niraparib In Recurrent IDH 1/2 Gliomas
Massachusetts General Hospital
NCT05406700
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03213704
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Prelude Therapeutics
NCT04089449
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03526250
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Recurrent Glioma Trial Landscape
ClinicalTrials.gov lists 13 US studies indexed under Recurrent Glioma, and 4 of those are currently open to recruitment — roughly 31% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Recurrent Glioma shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 10 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Recurrent Glioma is led by National Cancer Institute (NCI) with 5 indexed trials, alongside 8 other organizations in the top contributor list. The list on this page surfaces up to 13 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Recurrent Glioma?
PlainTrial tracks 13 US clinical trials for Recurrent Glioma, of which 4 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Recurrent Glioma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.